Vireo Growth (VREOD) Stock Price, News & Analysis

Company Overview

Vireo Growth Inc. is a cannabis company focused on the cultivation, processing, manufacturing and retail distribution of medical and adult-use cannabis products in select U.S. markets. The company operates through state-licensed subsidiaries and serves consumers through its retail locations and branded product offerings.

Its products may include cannabis flower, pre-rolls, vaporizers, concentrates, edibles, tinctures and topical products, depending on the regulations and product approvals in each market. Vireo has also operated retail dispensaries under the Green Goods brand.

The company was founded in 2014 by physician Kyle Kingsley and initially concentrated on medical cannabis markets. Vireo Growth has expanded its operations as additional states established regulated cannabis programs, while continuing to emphasize cultivation, product development and compliant retail operations.

Key Stats

• Today's Range: $9.95 to $9.95
• 50-Day Range: $9.95 to $9.95
• 52-Week Range: $8.91 to $24.00
• Volume: N/A
• Average Volume: 14,588 shs
• Market Capitalization: $450.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Vireo Growth Stock Analysis - MarketRank™

Vireo Growth scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Vireo Growth has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Vireo Growth has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 200.00%

Earnings Growth

Earnings for Vireo Growth are expected to grow by 200.00% in the coming year, from $0.30 to $0.90 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vireo Growth is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vireo Growth is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vireo Growth has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for VREOD.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vireo Growth does not currently pay a dividend.

Dividend Growth

Vireo Growth does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.61

News Sentiment

Vireo Growth has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Vireo Growth this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vireo Growth insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.80% of the stock of Vireo Growth is held by insiders.

Percentage Held by Institutions

Vireo Growth has minimal institutional ownership at this time.

Company Calendar

• Today: 10/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:VREOD
• Previous Symbol: OTCMKTS:GDNSF
• CIK: 1771706
• Web: goodnessgrowth.com
• Phone: (612) 999-1606
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 33.17
• P/E Growth: N/A
• Net Income: -$68.11 million
• Net Margins: -23.37%
• Pretax Margin: -11.22%
• Return on Equity: -19.76%
• Return on Assets: -7.15%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 1.20
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $268.77 million
• Price / Sales: 1.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.73 per share
• Price / Book: 1.14

Miscellaneous

• Outstanding Shares: 45,315,000
• Free Float: 43,593,000
• Market Cap: $450.88 million
• Optionable: Not Optionable
• Beta: 1.78